Company: MYGN
Filing Date: 2025-02-24
Form Type: 8-K
Source: 0000899923-25-000010
Chunk: 3

Company: MYRIAD GENETICS INC
Filing Date: 2025-02-24
Form: 8-K
Item: Item 2.02
Chunk 3
---
 is not complete and is qualified in its entirety by reference to the full text of the Raha Employment Agreement and the Raha Severance and Change of Control Agreement, copies of which are filed as Exhibit 10.1 and 10.2, respectively, to this Current Report on Form 8-K.

There are no arrangements or understandings between Mr. Raha and any other person pursuant to which he was appointed as an officer and a director of the Company. Mr. Raha does not have any family relationship with any director or other executive officer of the Company and is not party to any related party transactions required to be reported pursuant to Item 404(a) of Regulation S-K.

Appointment of Mark S. Verratti as Chief Operating Officer

On February 24, 2025, the Board also appointed Mark S. Verratti, the Company’s current Chief Commercial Officer, as its Chief Operating Officer as of the Effective Date to succeed Mr. Raha in this position.

Mr. Verratti, 56, has served as Chief Commercial Officer of the Company since April 2022. He previously served as President, Mental Health or President, Myriad Neuroscience from August 2017 to April 2022, and as President of Myriad Autoimmune from May 2020 until the sale of the Myriad Autoimmune business in September 2021. Prior to his appointment as President, Myriad Neuroscience, he served as SVP, Chief Sales and Business Development Officer at Assurex Health since January 2016. Mr. Verratti also held senior leadership positions worldwide with Cyberonics (now known as LivaNova) from 2005-2016, and earlier with Forest Pharmaceuticals where he led commercial teams with revenues approaching $500 million dollars. Mr. Verratti received a B. S. in Life Sciences with a minor in Physiology from The Pennsylvania State University.

In connection with his new appointment, on February 24, 2025, the Company entered into an employment agreement with Mr. Verratti (the “ Verratti Employment Agreement”) setting forth Mr. Verratti’s compensation and certain other terms with respect to his employment as Chief Operating Officer of the Company. Pursuant to the Verratti Employment Agreement, Mr. Verratti will become Chief Operating Officer of the Company as of the Effective Date, at which time he will be paid an annual base salary of $660,000. Mr. Verratti will be eligible to receive an annual target cash bonus equal